Fasting or Nonfasting Lipid Measurements It Depends on the Question

Journal of the American College of Cardiology

Volumn 67, Issue 10, 2016, Pages 1227-1234

  Driver, Steven L ^a   Martin, Seth S ^b   Gluckman, Ty J ^c,d   Clary, Julie M ^d   Blumenthal, Roger S ^b   Stone, Neil J ^a  

^a NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Providence Heart and Vascular Institute   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cholesterol; Key Words atherosclerotic cardiovascular disease; primary prevention; secondary prevention; statins; triglycerides

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; LIPID;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; DIET RESTRICTION; DYSLIPIDEMIA; FAMILIAL DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GENETIC DISORDER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPERTRIGLYCERIDEMIC PANCREATITIS; LIFESTYLE; LIPID ANALYSIS; METABOLIC SYNDROME X; NON FASTING; PANCREATITIS; PATIENT COUNSELING; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SECONDARY PREVENTION; BLOOD; CARDIOVASCULAR DISEASES; HEALTH; MORBIDITY; PRACTICE GUIDELINE; PROCEDURES; RISK FACTOR; TRENDS;

CARDIOVASCULAR DISEASES; FASTING; GLOBAL HEALTH; HUMANS; LIPIDS; MORBIDITY; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; SECONDARY PREVENTION;

EID: 84961231254     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.12.047     Document Type: Review

References (45)

1. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2889 2934
2. D.S. Fredrickson, R.I. Levy, and R.S. Lees Fat transport in lipoproteins- A n integrated approach to mechanisms and disorders N Engl J Med 276 1967 148 156
3. W.T. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
5. S.S. Martin, L.S. Sperling, M.J. Blaha, and et al. Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: Importance to implementation of the 2013 ACC/AHA Guidelines J Am Coll Cardiol 65 2015 1361 1368
6. K.M. Johnson, and D.A. Dowe Accuracy of statin assignment using the 2013 AHA/ACC Cholesterol Guideline versus the 2001 NCEP ATP III guideline: Correlation with atherosclerotic plaque imaging J Am Coll Cardiol 64 2014 910 919
7. B. Doran, Y. Guo, J. Xu, and et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: Insight from the National Health and Nutrition Examination Survey III (NHANES-III) Circulation 130 2014 546 553
8. S.S. Martin, M.J. Blaha, M.B. Elshazly, and et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile JAMA 310 2013 2061 2068
9. W.G. Miller, P.P. Waymack, F.P. Anderson, and et al. Performance of four homogeneous direct methods for LDL-cholesterol Clin Chem 48 2002 489 498
10. J. Ordóñez-Llanos, A.M. Wägner, R. Bonet-Marqués, and et al. Which cholesterol are we measuring with the Roche direct, homogeneous LDL-C plus assay? Clin Chem 47 2001 124 126
11. M.B. Elshazly, S.S. Martin, M.J. Blaha, and et al. Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: The VLDL-2 study (very large database of lipids) J Am Coll Cardiol 62 2013 1960 1965
12. T. Sathyapalan, S.L. Atkin, and E.S. Kilpatrick Variability of lipids in patients with type 2 diabetes taking statin treatment: Implications for target setting Diabet Med 25 2008 909 915
13. G. Bardini, I. Dicembrini, C.M. Rotella, and et al. Lipids seasonal variability in type 2 diabetes Metabolism 61 2012 1674 1677
14. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
15. M.C. Tattersall, R.E. Gangnon, K.N. Karmali, and et al. Women up, men down: The clinical impact of replacing the Framingham Risk Score with the Reynolds Risk Score in the United States population PLoS One 7 2012 e44347
16. J.J. Genest Jr., S.S. Martin-Munley, J.R. McNamara, and et al. Familial lipoprotein disorders in patients with premature coronary artery disease Circulation 85 1992 2025 2033
17. J.W. Knowles, E.C. O'Brien, K. Greendale, and et al. Reducing the burden of disease and death from familial hypercholesterolemia: A call to action Am Heart J 168 2014 807 811
18. A. Sniderman, A. Tremblay, J. Bergeron, and et al. Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B J Clin Lipidol 1 2007 256 263
19. R.W. Mahley, Y. Huang, and S.C. Rall Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes J Lipid Res 40 1999 1933 1949
20. P.N. Hopkins, E.A. Brinton, and M.N. Nanjee Hyperlipoproteinemia type 3: The forgotten phenotype Curr Atheroscler Rep 16 2014 440
21. M. Royer, C. Bulai Livideanu, B. Periquet, and et al. [Orange skin and xanthomas associated with lycopenaemia in a setting of type III dyslipoproteinemia] Ann Dermatol Venereol 136 2009 42 45
22. D.J. Blom, F.H. O'Neill, and A.D. Marais Screening for dysbetalipoproteinemia by plasma cholesterol and apolipoprotein B concentrations Clin Chem 51 2005 904 907
23. D.W. Lam, and D. LeRoith Metabolic Syndrome L.J. De Groot, P. Beck-Peccoz, G. Chrousos, Endotext [online] 2000 MDText.com, Inc. South Dartmouth, MA updated 2015 Available at: Http://www.ncbi.nlm.nih.gov.ezproxy.galter.northwestern.edu/books/NBK278936/. Accessed September 27, 2015
24. I. Lemieux, A. Pascot, C. Couillard, and et al. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 102 2000 179 184
25. A. Galassi, K. Reynolds, and J. He Metabolic syndrome and risk of cardiovascular disease: A meta-analysis Am J Med 119 2006 812 819
26. G.M. Reaven Is diagnosing metabolic syndrome a uniquely simple way to predict incident type 2 diabetes mellitus? Can Med Assoc J 180 2009 601 602
27. M.F. Jumean, Y. Korenfeld, V.K. Somers, and et al. Impact of diagnosing metabolic syndrome on risk perception Am J Health Behav 36 2012 522 532
28. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
29. R.T. Ackermann Working with the YMCA to implement the Diabetes Prevention Program Am J Prev Med 44 2013 S352 S356
30. C.A. Pellegrini, J.M. Duncan, A.C. Moller, and et al. A smartphone-supported weight loss program: Design of the ENGAGED randomized controlled trial BMC Public Health 12 2012 1041
31. S. Mora, N.K. Wenger, D.A. Demicco, and et al. Determinants of residual risk in secondary prevention patients treated with high-versus low-dose statin therapy: The Treating to New Targets (TNT) study Circulation 125 2012 1979 1987
32. P. Kohli, D.D. Waters, R. Nemr, and et al. Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: An analysis from TNT and IDEAL J Am Coll Cardiol 65 2015 402 404
33. P.H. Joshi, S.S. Martin, and R.S. Blumenthal The remnants of residual risk J Am Coll Cardiol 65 2015 2276 2278
34. M. Miller, C.P. Cannon, S.A. Murphy, et al. for the PROVE IT-TIMI 22 Investigators Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial J Am Coll Cardiol 51 2008 724 730
35. G.G. Schwartz, M. Abt, W. Bao, and et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins J Am Coll Cardiol 65 2015 2267 2275
36. S. Rabar, M. Harker, N. O'Flynn, and et al. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: Summary of updated NICE guidance Br Med J 349 2014 g4356
37. R.H. Eckel, J.M. Jakicic, J.D. Ard, and et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2960 2984
38. P.M. Ridker, E. Danielson, F.A. Fonseca, et al. for the JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
39. S. Mora, R.J. Glynn, S.M. Boekholdt, and et al. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin) J Am Coll Cardiol 59 2012 1521 1528
40. R. Puri, S.E. Nissen, M. Shao, and et al. Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy Am J Cardiol 114 2014 1465 1472
41. Y. Kataoka, J. St John, K. Wolski, and et al. Atheroma progression in hyporesponders to statin therapy Arterioscler Thromb Vasc Biol 35 2015 990 995
42. N.K. Choudhry, J. Avorn, R.J. Glynn, and et al. Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial. Full coverage for preventive medications after myocardial infarction N Engl J Med 365 2011 2088 2097
43. M. Miller, N.J. Stone, C. Ballantyne, et al. American Heart Association Clinical Lipidology Thrombosis, and Prevention Committee of the Council on Nutrition Physical Activity, and Metabolism Council on Arteriosclerosis, Thrombosis and Vascular Biology Council on Cardiovascular Nursing, and Council on the Kidney in Cardiovascular Disease Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association Circulation 123 2011 2292 2333
44. C. Dubois, G. Beaumier, C. Juhel, and et al. Effects of graded amounts (0-50 g) of dietary fat on postprandial lipemia and lipoproteins in normolipidemic adults Am J Clin Nutr 67 1998 31 38
45. K.T. White, M.V. Moorthy, A.O. Akinkuolie, and et al. Identifying an optimal cutpoint for the diagnosis of hypertriglyceridemia in the nonfasting state Clin Chem 61 2015 1156 1163